首页> 外文期刊>Veterinary research >Salmonella enterica serovar Choleraesuis vector delivering SaoA antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs
【24h】

Salmonella enterica serovar Choleraesuis vector delivering SaoA antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs

机译:传递SaoA抗原的沙门氏菌血清霍乱弧菌载体赋予小鼠和猪抗猪链球菌2型和7型血清型的保护

获取原文
获取外文期刊封面目录资料

摘要

Streptococcus suis is one of the major pathogens that cause economic losses in the swine industry worldwide. However, current bacterins only provide limited prophylactic protection in the field. An ideal vaccine against S. suis should protect pigs against the clinical diseases caused by multiple serotypes, or at least protect against the dominant serotype in a given geographic region. A new recombinant Salmonella enterica serotype Choleraesuis vaccine vector, rSC0011, that is based on the regulated delayed attenuation system and regulated delayed antigen synthesis system, was developed recently. In this study, an improved recombinant attenuated Salmonella Choleraesuis vector, rSC0016, was developed by incorporating a sopB mutation to ensure adequate safety and maximal immunogenicity. In the spleens of mice, rSC0016 colonized less than rSC0011. rSC0016 and rSC0011 colonized similarly in Peyer’s patches of mice. The recombinant vaccine rSC0016(pS-SaoA) induced stronger cellular, humoral, and mucosal immune responses in mice and swine against SaoA, a conserved surface protein that is present in many S. suis serotypes, than did rSC0011(pS-SaoA) without sopB or rSC0018(pS-SaoA), which is an avirulent, chemically attenuated vaccine strain. rSC0016(pS-SaoA) provided 100% protection against S. suis serotype 2 in mice and pigs, and full cross-protection against SS7 in pigs. This new vaccine vector provides a foundation for the development of a universal vaccine against multiple serotypes of S. suis in pigs.
机译:猪链球菌是导致全球养猪业经济损失的主要病原体之一。但是,目前的细菌素在该领域仅提供有限的预防保护。理想的抗猪链球菌疫苗应能保护猪免受多种血清型引起的临床疾病的侵害,或至少能防止给定地理区域内的优势血清型的侵害。最近开发了一种新的重组小肠沙门氏菌血清型霍乱疫苗载体rSC0011,该载体基于调控的延迟减毒系统和调控的延迟抗原合成系统。在这项研究中,通过整合sopB突变开发了一种改良的重组减毒霍乱沙门氏菌霍乱沙门氏菌载体rSC0016,以确保足够的安全性和最大的免疫原性。在小鼠脾脏中,rSC0016的定殖少于rSC0011。 rSC0016和rSC0011同样在Peyer的小鼠斑块中定植。与没有sopB的rSC0011(pS-SaoA)相比,重组疫苗rSC0016(pS-SaoA)在小鼠和猪中诱导了针对SaoA的更强的细胞,体液和粘膜免疫反应,SaoA是许多猪链球菌血清型中存在的保守表面蛋白。或rSC0018(pS-SaoA),它是一种无毒的化学减毒疫苗株。 rSC0016(pS-SaoA)在小鼠和猪中提供了针对猪链球菌血清型2的100%保护,并在猪中对SS7进行了全面交叉保护。这种新的疫苗载体为开发针对猪中多种血清型猪链球菌的通用疫苗奠定了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号